Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 2:5:7.
doi: 10.1038/s41525-020-0116-5. eCollection 2020.

The special considerations of gene therapy for mitochondrial diseases

Affiliations
Review

The special considerations of gene therapy for mitochondrial diseases

Jesse Slone et al. NPJ Genom Med. .

Abstract

The recent success of gene therapy across multiple clinical trials has inspired a great deal of hope regarding the treatment of previously intractable genetic diseases. This optimism has been extended to the prospect of gene therapy for mitochondrial disorders, which are not only particularly severe but also difficult to treat. However, this hope must be tempered by the reality of the mitochondrial organelle, which possesses specific biological properties that complicate genetic manipulation. In this perspective, we will discuss some of these complicating factors, including the unique pathways used to express and import mitochondrial proteins. We will also present some ways in which these challenges can be overcome by genetic manipulation strategies tailored specifically for mitochondrial diseases.

Keywords: Diseases; Genetics research; Medical genetics.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Expression of a putative nuclear-encoded mitochondrial protein using a recombinant viral vector.
The majority of the proteins required for mitochondrial function (~1500) are encoded by the nuclear genome (nDNA), while a small subset of proteins (13), 22 tRNA and 2 rRNA are encoded by the mitochondrial genome (mtDNA). In the case of proteins encoded by the nuclear genome, restoration of protein function will involve transduction of the recombinant viral vector, transcription of the transgene, and translation of the protein in the cytosol (a), followed by transportation of the protein into the mitochondria through specialized import pathways (b). Most nuclear-encoded proteins are imported as precursors through the general “translocase of the outer membrane” (TOM) complex, which is located in the outer membrane. Subsequent import mechanisms differ based on the structure and function of the mitochondrial protein, as well as its ultimate destination. In the case of the example shown here, which is a protein destined for one of the respiratory complexes of the IMM, a “translocase of inner membrane” complex such as TIM23 (not shown) will interact with the TOM complex to facilitate insertion of the respiratory complex protein into the IMM. In contrast, mtDNA-encoded proteins are synthesized inside the matrix, and co-translationally inserted into the inner mitochondrial membrane to form complexes with their nDNA-encoded partners. By default, any proteins encoded by gene therapy vectors such as AAV will also be translated in cytosol like any other nDNA-encoded protein. Thus, in order to allotopically express an mtDNA-encoded protein from the nucleus, additional modification of a mtDNA-encoded protein will be required to make sure that it is imported to its proper location inside the mitochondria. Abbreviations: OMM (outer mitochondrial membrane), IMM (inner mitochondrial membrane), IMS (Intermembrane space), mtDNA (mitochondrial DNA), AAV (adeno-associated Virus).

References

    1. Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–860. doi: 10.1016/S0140-6736(17)31868-8. - DOI - PMC - PubMed
    1. Al-Zaidy, S. et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr. Pulmonol.54, 179–185 (2019). - PMC - PubMed
    1. Thompson AA, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N. Engl. J. Med. 2018;378:1479–1493. doi: 10.1056/NEJMoa1705342. - DOI - PubMed
    1. Galanello R, Origa R. Beta-thalassemia. Orphanet J. Rare Dis. 2010;5:11. doi: 10.1186/1750-1172-5-11. - DOI - PMC - PubMed
    1. High KA, Roncarolo MG. Gene Therapy. N. Engl. J. Med. 2019;381:455–464. doi: 10.1056/NEJMra1706910. - DOI - PubMed